Combination of citalopram and nortriptyline in the treatment of moderate to severe major depression: a double-blind placebo-controlled trial

Tehran University of Medical Sciences (Iran)0 个研究点目标入组 45 人开始时间: 2005年6月20日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•After giving informed consent and discontinuing all psychotropic medications for 2 weeks, 45 outpatients (28 female and 17 male) between 18 and 54 years of age were enrolled in the study. Seven subjects dropped out after the first week of treatment due to noncompliance (3 subjects from group 1 and 4 subjects from group 2) leaving 38 patients (24 female and 14 male) who completed the trial. All subjects met the Diagnostic and Statistical Manual of Mental Disorders, Fourth edition (DSM-IV) criteria for major depressive disorder (MDD), based on the structured clinical interview for DSM-IV and had a baseline Hamilton Rating scale for depression (HAM-D, 17 item) score of at least 20. The HAM-D is, the most widely used physician-administrated rating scale for depression, summates 17 individual item scores to provide a total score indicative of the severity of depression.

•Patients with a history of other psychiatric disorders, history of bipolar disorder, personality disorder, anxiety disorder, substance abuse, alcoholism, and organic brain disorders were excluded. Also patients were excluded if they were psychotic or posed a significant risk of suicide at any time during participation. Pregnant or lactating women were excluded. All patients were free of unstable medical disorders including cardiovascular, hepatic, renal, gastrointestinal, pulmonary, metabolic, endocrine or hematological illnesses.

发起方

Tehran University of Medical Sciences (Iran)